Chief Medical Officer
Jonathan Rubin, MD, MBA is a Developmental-Behavioral Pediatrician with 25 years of expertise related to ADHD. While Chief Medical Officer at Alcobra Pharmaceuticals, he provided oversight of IND applications, phase I-IV studies, and assisted with successful Orphan and Fast Track designations.
Prior to Alcobra, Jonathan worked in Medical Affairs and Clinical Development across the Shire Pharmaceuticals ADHD portfolio including the initial launch and co-administration launch of Intuniv.
Prior to Shire, Jonathan practiced in South Florida, where he specialized in Pediatrics and Developmental-Behavioral Pediatrics. He obtained an MBA from Columbia Business School, MD from the University of Connecticut School of Medicine, and BS from Yale University. He completed a Pediatric Residency at Albert Einstein/Montefiore and an Ambulatory Pediatrics fellowship at Boston Children’s Hospital.